Stock listing
A41YK5 Stock Price, News, Filings & Events — Clearmind Medicine Inc.
Selected listing: A41YK5 · LSX · EUR · DE
This page tracks Clearmind Medicine Inc.'s A41YK5:LSX listing on LSX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A41YK5:LSX. A41YK5:LSX is the stock-level entry point for investors researching Clearmind Medicine Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- A41YK5:LSX
- Asset type
- Stock
- Market cap
- $2.6M
- Sector
- Non-Energy Minerals
- Industry
- Other Metals/Minerals
- Exchange
- LSX
- Currency
- EUR
Clearmind Medicine Inc. A41YK5:LSX stock context
This page tracks Clearmind Medicine Inc.'s A41YK5:LSX listing on LSX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A41YK5:LSX. A41YK5:LSX is the stock-level entry point for investors researching Clearmind Medicine Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Clearmind Medicine Inc.
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
September 1, 2026
Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
August 24, 2026
Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint
August 13, 2026
Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Com...
August 11, 2026
Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems C...
August 3, 2026
Research Clearmind Medicine Inc.
Clearmind Medicine Inc. investor report
Review AI stock analysis and investor report context for A41YK5:LSX.
Clearmind Medicine Inc. company profile
View the public company page for Clearmind Medicine Inc. on 6ix.
Clearmind Medicine Inc. news
Read company news and market updates connected to Clearmind Medicine Inc..
Clearmind Medicine Inc. investor events
Find investor webinars, events, and replay context for Clearmind Medicine Inc..
Alternate listings
CMND:NASDAQ
US · USD
Alternate listing for Clearmind Medicine Inc.; the primary context on this page is A41YK5:LSX.
CMND:BOATS
US · USD
Alternate listing for Clearmind Medicine Inc.; the primary context on this page is A41YK5:LSX.
CWY:GETTEX
DE · EUR
Alternate listing for Clearmind Medicine Inc.; the primary context on this page is A41YK5:LSX.
A41YK5:LS
DE · EUR
Alternate listing for Clearmind Medicine Inc.; the primary context on this page is A41YK5:LSX.
CWY0:FWB
DE · EUR
Alternate listing for Clearmind Medicine Inc.; the primary context on this page is A41YK5:LSX.
A427B1:LS
DE · EUR
Alternate listing for Clearmind Medicine Inc.; the primary context on this page is A41YK5:LSX.
CWY:MUN
DE · USD
Alternate listing for Clearmind Medicine Inc.; the primary context on this page is A41YK5:LSX.
CWY0:MUN
DE · EUR
Alternate listing for Clearmind Medicine Inc.; the primary context on this page is A41YK5:LSX.